Analysis of AC3-33 gene expression in multiple organ cancer and adjacent normal tissue by RNA in situ hybridization
- Authors:
- Fen Hu
- Shaoqing Yang
- Shaobo Lv
- Yan Peng
- Lijun Meng
- Lixia Gou
- Xiujun Zhang
View Affiliations
Affiliations: College of Life Sciences, College of Psychology, Hebei United University, Tangshan, Hebei 063000, P.R. China, Department of Environment and Chemical Engineering, Tangshan College, Tangshan, Hebei 063000, P.R. China
- Published online on: April 14, 2015 https://doi.org/10.3892/ol.2015.3112
-
Pages:
2795-2798
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
The AC3-33 gene encodes a secretory protein that can inhibit Elk1 transcriptional activity via the ERK1/2 pathway. In the current study, in situ RNA hybridization was used to detect the AC3‑33 gene expression in multiple organ cancer and cancer‑adjacent normal tissue. The results showed that the expression level of AC3‑33 varies across different tissues. AC3‑33 exhibited positive expression in squamous cell carcinoma of the esophagus, adenocarcinoma of the rectum, hepatocellular carcinoma, squamous cell carcinoma (SCC) of the lung, cancer‑adjacent normal hepatic tissue, clear cell carcinoma of the kidney, invasive ductal carcinoma of the breast, SCC of the uterine cervix and cancer‑adjacent normal kidney tissue. Negative expression of AC3‑33 was observed in adenocarcinoma of the stomach and colon, cancer‑adjacent normal esophageal tissue, cancer‑adjacent normal gastric tissue, cancer‑adjacent normal colon tissue, cancer‑adjacent normal rectal tissue, serous adenocarcinoma of the ovary and cancer‑adjacent normal ovarian tissue. However, the expression of AC3‑33 in cancer adjacent normal breast tissue was partially positive. In conclusion, the AC3‑33 gene does exhibit positive expression in certain carcinomas, which may indicate that AC3-33 has a significant involvement in the development and progression of these carcinomas.
View References
|
1
|
Zhang X, Ma X, Xue Y, et al: Prokaryotic
expression and characterization of human AC3-33 protein. Front
Biosci (Elite Ed). 2:1134–1142. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Angel P and Karin M: The role of Jun, Fos
and the AP-1 complex in cell-proliferation and transformation.
Biochim Biophys Acta. 1072:129–157. 1991.PubMed/NCBI
|
|
3
|
Hao D, Gao P, Liu P, et al: AC3-33, a
novel secretory protein, inhibits Elk1 transcriptional activity via
ERK pathway. Mol Biol Rep. 38:1375–1382. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Liu P, Deng WW, Gao P, et al: Molecular
cloning and preliminary function study of a novel human gene AC3-33
related to suppress AP-1 activity. Yi Chuan. 30:575–582. 2008.(In
Chinese). View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bollschweiler E and Holscher AH: Carcinoma
of the esophagus-actual epidemiology in Germany. Onkologie.
24:180–184. 2001.(In German). View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Suita S, Zaizen Y, Kaneko M, et al: What
is the benefit of aggressive chemotherapy for advanced
neuroblastoma with N-myc amplification? A report from the Japanese
study group for the treatment of advanced neuroblastoma. J Pediatr
Surg. 29:746–750. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kitagawa Y, Ueda M, Ando N, Shinozawa Y,
Shimizu N and Abe O: Significance of int-2/hst-1 coamplification as
a prognostic factor in patients with esophageal squamous carcinoma.
Cancer Res. 51:1504–1508. 1991.PubMed/NCBI
|
|
8
|
Shinozaki H, Ozawa S, Ando N, et al:
Cyclin D1 amplification as a new predictive classification for
squamous cell carcinoma of the esophagus, adding gene information.
Clin Cancer Res. 2:1155–1161. 1996.PubMed/NCBI
|
|
9
|
Yamasaki M, Miyata H, Fujiwara Y, et al:
p53 genotype predicts response to chemotherapy in patients with
squamous cell carcinoma of the esophagus. Ann Surg Oncol.
17:634–642. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
National Cancer Institute, . Colon Cancer
Treatment (PDQ®). http://www.cancer.gov/cancertopics/pdq/treatment/colon/Patient/page1/AllPagesAccessed.
29–June. 2014
|
|
11
|
Comprehensive molecular characterization
of human colon and rectal cancer. Nature. 487:330–337. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Olson RM, Perencevich NP, Malcolm AW,
Chaffey JT and Wilson RE: Patterns of recurrence following curative
resection of adenocarcinoma of the colon and rectum. Cancer.
45:2969–2974. 1980. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ratto C, Sofo L, Ippoliti M, Merico M,
Doglietto GB and Crucitti F: Prognostic factors in colorectal
cancer. Literature review for clinical application. Dis Colon
Rectum. 41:1033–1049. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jurach MT, Meurer L and Moreira LF:
Expression of the p53 protein and clinical and pathologic
correlation in adenocarcinoma of the rectum. Arq Gastroenterol.
43:9–14. 2016.
|
